Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof-of-mechanism Single-center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate Pharmacodynamics, Safety, Tolerability and Exposure of BAY2586116 (Part A) and an Open-label Comparison of Different Application Modes for Single Nasal/Pharyngeal Dose Administrations (Part B) in 12 Participants With Obstructive Sleep Apnea

Next Previous
Trial Profile

Proof-of-mechanism Single-center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate Pharmacodynamics, Safety, Tolerability and Exposure of BAY2586116 (Part A) and an Open-label Comparison of Different Application Modes for Single Nasal/Pharyngeal Dose Administrations (Part B) in 12 Participants With Obstructive Sleep Apnea

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BAY 2586116 (Primary) ; BAY 2586116 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms KOALA
  • Sponsors Bayer

Most Recent Events

  • 09 Jul 2021 Status changed from active, no longer recruiting to completed.
  • 18 Jun 2021 Planned End Date changed from 11 Jun 2021 to 28 Jun 2021.
  • 19 Feb 2021 Planned End Date changed from 7 May 2021 to 11 Jun 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top